ACCU-BREAK(TM) Tablet-Splitting Technologies Introduced at 2007 American Society of Hypertension Meeting.

PLANTATION, Fla. -- ACCU-BREAK Pharmaceuticals, Inc. ("ABP") announced today that its innovative tablet-splitting technologies are being introduced at an important scientific conference. ABP's Accu-Break[TM] technologies are the subjects of two posters at the American Society of Hypertension (ASH) 22nd Annual Scientific Meeting and Exposition in Chicago on May 19-22. ASH is the largest U.S. organization dedicated exclusively to hypertension and related cardiovascular disease.

Barry J. Materson, MD, MBA, Professor of Medicine, University of Miami Leonard M. Miller School of Medicine (Miami, FL), will present two posters on Monday, May 21 at 12:00 p.m. Each poster highlights a different capability made possible by the use of a drug-free layer in the tablet. This drug-free zone serves as the break region of the tablet if a partial dose of the drug is desired. The first poster that Dr. Materson will present is titled A Novel Tablet Structure for Fixed-Dose Combination Products [poster #408.]; the second is ACCU-BREAK Technology for Precise Dosing with Split Tablets [poster #409].

"The primary advantage of an Accu-Break tablet's design for the medical community is more accurate, individualized dosage adjustment and titration," explains Dr. Materson. "Products that are developed with these tablet designs may in turn lead to more consistent therapeutic effects, fewer side effects and enhanced adherence to treatment plans."

The Accu-Break Technologies

Difficult and uneven tablet-splitting is a longstanding clinical problem with potentially important implications for patient safety and drug efficacy. For this reason, organizations such as the American Medical Association and the American Pharmacists Association formally oppose mandatory pill splitting. Research has shown that the actual dosages of hand-split tablets may deviate by more than 20% from the predicted half dose, and that many tablets are physically difficult for some patients to break.

ABP believes that for the first time, tablets that break unevenly will be able to provide equal doses because of the unique drug-free break region. The Accu-Break tablet design is intended to provide tablets that are both easy to swallow whole and easy to grasp and split through the drug-free break region.

Lawrence Solomon, MD, FACC, Founder, Chairman and Chief Executive Officer of ABP, states: "As a physician, my motivation for focusing on the development of Accu-Break technologies is the belief that millions of patients can be better treated if their medicines are manufactured not only to be taken whole, but also to be easily broken to create precise half or quarter doses. We at ABP look forward to the day when Accu-Break tablets will be standard for the many drugs that undergo dosage adjustment."

About ACCU-BREAK Pharmaceuticals, Inc.

ACCU-BREAK Pharmaceuticals (ABP) is a privately held development stage pharmaceutical company led by an experienced management team drawn from the worlds of medicine and the pharmaceutical industry. ABP has filed a number of U.S. patents related to its unique technologies. To learn more about the company and its technologies, visit www.accubreak.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Shareholders are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.

Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Note to reporters/editors: Dr. Materson and Richard Berger, MD, FACC (Medical Director, ABP) will be on-site at the scheduled Accu-Break poster sessions to answer questions and discuss the technologies.